Science

Science Corporation operates at the intersection of neurotechnology, medical devices, and neural-engineering research. Its portfolio spans PRIMA, an implantable visual prosthesis; Biohybrid BCI work; and the Science Ecosystem, which combines neural hardware, software, probes, and fabrication capabilities. That combination gives the company a broader platform scope than a single-device developer, while PRIMA provides a focused clinical and commercial pathway in retinal restoration. The company’s platform also serves research and development needs through products such as SciFi, Axon probes, Synapse Protocol, and Science Foundry services. The competitive landscape should therefore be assessed across retinal implants, invasive and non-invasive BCIs, and neural research platforms rather than through an unsupported direct ranking. Science’s differentiators are its combination of a vision-restoration program with vertically integrated neural-engineering tools and fabrication.

Science Corporation’s financing history shows a step-up in capital as it has advanced from company formation toward clinical translation and broader platform development. Founded in 2021, it raised a $47,324,986 Seed round that year, followed by a $25,999,998 Venture Round in 2024 and a $104 million Convertible Note in April 2025. Its $230 million Series C on Mar 5, 2026 brought the structured funding total to $407,324,984. PRIMA’s European approval and rollout in July 2026, followed by the October 2026 announcement of 36-month trial results, mark key inflection points for the clinical program. At the same time, the February 2026 Neurosoft partnership extends the potential reach of Science’s clinical-grade BCI ecosystem beyond its own products. Leadership additions in 2026—including Darius Shahida as chief strategy officer, Murat Günel as BCI medical director, and Nevada Sanchez as engineering EVP—add expertise across corporate development, clinical work, and engineering. The company is listed in the 101–250 employee band and reports active hiring across BCI, clinical, and engineering roles.